AbbVie Advises Doctors to Stop Prescribing Technivie and Viekira XR
May 21, 2018 – In anticipation of withdrawing its products Technivie® (ombitasvir/ paritaprevir/ritonavir) and Viekira XR™ (dasabuvir/ombitasvir/paritaprevir/ritonavir) from the market, AbbVie has asked physicians to no longer prescribe these hepatitis C treatments as of July 1, 2018.
AbbVie plans to discontinue manufacturing of both Technivie and Viekira XR by the end of the year. However, the company has stated that it will ensure sufficient supplies are available for patients to complete a 12-week or 24-week course if they begin treatment with either product by the end of June 2018. Originally approved in 2014 (Viekira XR) and 2015 (Technivie), both drugs remain safe and effective, according to the manufacturer. AbbVie has stated it is removing the products from the market for business reasons.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.